CAMBRIDGE, Mass. (September 27, 2012) – For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein ...

Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does ...

The c-Myc oncoprotein is frequently overexpressed in human cancers and is essential for cancer cell proliferation. The dysregulation of ubiquitin-proteasome-mediated degradation is one of the ...

Scientists at the Karolinska Institutet in Sweden have found a new region in the c-Myc oncogene that would allow the development of a binding compound to target it. Their discovery is based on a ...

Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer. The study is now published in Nature ...

A promising new treatment to combat "undruggable" cancers has been green-lit for a human trial in 2025. It's hoped the novel drug will be able to stunt the growth and enable the effective treatment of ...

UCSF researchers have discovered that blocking the function of a certain type of immune cell halts pancreatic islet tumor growth in mice. The finding proves, they say, that specific immune cells can ...

This is a preview. Log in through your library . Abstract Lung cancer is a leading cause of cancer death worldwide; however, despite major advances in cancer treatment during the past two decades, the ...

Limited sensitivity to chemotherapy and an immunosuppressive tumor microenvironment drives breast cancer mortality in HER2 negative breast cancer. We have identified the IRE1/XBP1 branch of the ...